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Abstract
Introduction: Although many sepsis biomarkers have shown promise in selected patient groups, only C-reactive
protein and procalcitonin (PCT) have entered clinical practice. The aim of this study was to evaluate three
promising novel sepsis biomarkers in unselected patients at admission to intensive care. We assessed the
performance of pancreatic stone protein (PSP), soluble CD25 (sCD25) and heparin binding protein (HBP) in
distinguishing patients with sepsis from those with a non-infective systemic inflammatory response and the ability
of these markers to indicate severity of illness.
Methods: Plasma levels of the biomarkers, PCT and selected inflammatory cytokines were measured in samples
taken from 219 patients during the first six hours of admission to intensive or high dependency care. Patients with
a systemic inflammatory response were categorized as having sepsis or a non-infective aetiology, with or without
markers of severity, using standard diagnostic criteria.
Results: Both PSP and sCD25 performed well as biomarkers of sepsis irrespective of severity of illness. For both markers
the area under the receiver operating curve (AUC) was greater than 0.9; PSP 0.927 (0.887 to 0.968) and sCD25 0.902
(0.854 to 0.949). Procalcitonin and IL6 also performed well as markers of sepsis whilst in this intensive care unit (ICU)
population, HBP did not: PCT 0.840 (0.778 to 0.901), IL6 0.805 (0.739 to 0.870) and HBP 0.607 (0.519 to 0.694). Levels of
both PSP and PCT reflected severity of illness and both markers performed well in differentiating patients with severe
sepsis from severely ill patients with a non-infective systemic inflammatory response: AUCs 0.955 (0.909 to 1) and 0.837
(0.732 to 0.941) respectively. Although levels of sCD25 did not correlate with severity, the addition of sCD25 to either
PCT or PSP in a multivariate model improved the diagnostic accuracy of either marker alone.
Conclusions: PSP and sCD25 perform well as sepsis biomarkers in patients with suspected sepsis at the time of
admission to intensive or high dependency care. These markers warrant further assessment of their prognostic
value. Whereas previously published data indicate HBP has clinical utility in the emergency department, it did not
perform well in an intensive-care population.
Introduction
Sepsis is a common reason for admission to intensive care
and high dependency units and the incidence of sepsis
continues to rise [1]. The symptoms and signs of sepsis
are highly variable and this makes clinical recognition and
assessment of severity difficult. At key decision points,
such as at the point of admission to high dependency care,
doctors are confronted with conflicting pressures. On one
hand there is a drive to minimise unnecessary antibiotic
prescribing and on the other, there is compelling evidence
that timely and specific administration of antibiotics saves
lives [2]. Biomarkers can inform decision making in this
situation both by indicating the presence or absence of
infection in a patient who has a systemic inflammatory
response syndrome (SIRS), and as measures of severity or
prognosis [3].
A recent review of the sepsis biomarker literature iden-
tified 178 biomarkers evaluated in 3,370 studies and yet
only two have become widely used [4]. C-reactive protein
(CRP) has been in use for over 20 years but has poor spe-
cificity unless high cut-off levels are used. Procalcitonin
(PCT) appears to be more specific for infection and,
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unlike CRP, its levels appear to reflect severity and prog-
nosis. However, a recent meta-analysis challenged this [5]
and subsequent controlled trials of PCT-guided treat-
ment of sepsis have produced conflicting results [6,7].
There remains an urgent need for better markers of
sepsis.
A major challenge in evaluating new sepsis biomarkers
is the lack of any gold-standard test. Consequently, early
evaluation of biomarkers tends to involve very tightly clini-
cally-defined patient groups which do not reflect the het-
erogeneity which clinicians encounter. Several novel
biomarkers have recently demonstrated promise in the
early evaluation of patients for sepsis and the aim of this
study was to further evaluate some of the most promising
in unselected patients presenting to the ICU. This
approach was taken to provide a challenging, real-life
assessment of these markers to screen for those which
perform well enough to justify further evaluation in clini-
cal trials. We selected three novel candidate markers. Pan-
creatic Stone Protein (PSP), also known as regenerating
protein and lithostathine, is a lectin-binding protein, the
blood levels of which increase in inflammation. It is a
secretory protein produced by pancreatic acinar cells and
intestinal Paneth cells but its function is not clear. Elevated
levels occur in acute and chronic pancreatitis, chronic
renal failure and gastrointestinal malignancy [8,9], but
among trauma patients, levels of PSP rise when sepsis
develops [10]. High PSP levels at the onset of ventilator-
associated pneumonia and in patients with septic shock
predict mortality [11,12]. CD25 is the IL2 receptor alpha
chain and is expressed constitutively on regulatory,
FOXP3+, T cells. It is also expressed on effector T cells
following activation and may reflect the development of a
compensatory regulatory response [13]. Soluble CD25
(sCD25) has been found to be higher in patients with sep-
sis than in patients with non-infective SIRS [14]. Heparin
Binding Protein (HBP) is an inflammatory mediator con-
tained within neutrophil secretory and azurophilic gran-
ules which demonstrated superior sensitivity and
specificity to PCT and CRP in identifying patients with
severe sepsis in the emergency department [15]. Recent
ICU-based studies suggest HBP levels may commonly be
elevated among ICU patients and reflect the presence of
cardiovascular shock [16,17]. Data on prediction of mor-
tality are conflicting [16-18]. Here we assessed, first, the
performance of these markers in distinguishing patients
with sepsis from those with a non-infective systemic
inflammatory response and, secondly, the ability of these
markers to indicate severity of illness.
Materials and methods
Study population
We sought to enrol all admissions to the general inten-
sive care unit (ICU) (17 beds) and high dependency unit
(HDU) (8 beds) at Brighton and Sussex Hospitals NHS
trust between August 2010 and January 2011. Patients
were excluded if they were under 18 years of age or
where it was not possible to obtain patient consent or
consultee approval to enrol the patient within six hours
of admission. The ethical approval for the study defined
a consultee in accordance with the United Kingdom
Mental Capacity Act as a friend or relative willing to
advise on the likely wishes of the patient.
The study was approved by the North Wales Research
Ethics Committee (Central and East) reference number
10/WNo03/19. Written informed consent or consultee
approval to enrol was secured for all participants in the
study. All data were anonymised.
We collected baseline characteristics of the patients
including demographic information, Sequential Organ
Failure Assessment (SOFA) score in the first 24 hours,
comorbidities, site and type of infection, and blood tests.
Patients were followed up until discharge from the ICU/
HDU or death.
Blood was collected from patients within six hours of
their admission to the unit. Samples were taken into
sodium citrate tubes, centrifuged and plasma was stored
at -80°C until the end of the study when all samples
were analysed for each marker as a single batch.
Definitions
The 2001 International Sepsis Definitions Conference defi-
nitions of Systemic Inflammatory Response Syndrome
(SIRS) and sepsis were used [19], sepsis being defined as
SIRS plus either proven infection (on the basis of micro-
biological sampling or radiology) or probable infection
(considering the patient’s clinical presentation, white cell
count, CRP, radiology) and non-infective SIRS being
defined as SIRS associated with an established underlying
non-infective diagnosis and no reason to suspect any
on-going infection. Categorisation of subjects was made
independently by two members of the study team (ML
and SD) blind to the biomarker results and any disagree-
ments were resolved by discussion. A patient’s sepsis or
non-infective SIRS was defined as being severe if it was
associated with organ dysfunction (SOFA score of 2 or
more for any organ system) [19,20]
Cytokine and biomarker measurements
Cytokine levels (IL6, IL8, IL1b, granulocyte macrophage
colony stimulating factor (GMCSF), TNFa) were mea-
sured on a Luminex LX200 using Invitrogen’s Human
Inflammatory 5-Plex panel (Invitrogen/Life Technologies,
Darmstadt, Germany) and Millipore filter plates (VWR,
Darmstadt, Germany) as per the manufacturers’ instruc-
tions. PSP and HBP were measured on microplate assays
as previously described [15,20]. PCT was measured on a
Kryptor instrument (Brahms, Henningsdorf, Germany).
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Levels of sCD25 were measured on commercially avail-
able microplate assays (Human IL-2 sRa (sCD25) OptEIA
Set, Becton Dickenson, San Diego, CA, USA). All bio-
marker analyses were conducted blind to the clinical
data.
Statistical analysis
Continuous variables were described using the mean ±
SD for normally distributed data or the median (inter-
quartile range (IQR)), for non-normally distributed data.
Comparisons of group differences for continuous vari-
ables were made by one-way ANOVA or Mann-Whit-
ney test as appropriate. Categorical data were described
as the number of patients in each category with corre-
sponding percentages. The significance of differences in
proportions was tested by Chi-squared test.
The performance of each marker in identifying sepsis
or severe sepsis was assessed as area under a receiver
operating characteristic (ROC) curve. For each marker
ROC curves were used to derive cut-offs for sensitivity
and specificity in distinguishing sepsis from non-infective
SIRS.
To establish the potential for combinations of markers
to improve identification of sepsis and severe sepsis, we
first used univariate correlation (Spearman’s rho) to
assess the relationship between the markers. Since the
majority of continuous variables were non-linear, associa-
tions between levels of each parameter and sepsis or
severe sepsis were sought after dividing the values for
each marker into quartiles. Stepwise logistic regression
was then used to assess the impact of different combina-
tions of markers on differentiation of sepsis from non-
infective SIRS. Statistical analyses were performed in
SPSS 17.0 (IBM Corporation Somers, NY, USA) and
Prism 5 (GraphPad Software Inc. La Jolia, CA, USA). All
P-values were two-sided and statistical significance was
set at an a-value of 0.05.
Results
Base-line characteristics and outcome of the study
population
Between August 2010 and January 2011, 486 patients were
admitted to the HDU/ICU. For 267 no study blood sample
could be obtained within six hours of admission because
consultee approval could not be obtained in time. These
patients did not enter the study. Of the 219 patients
enrolled, 34 were admitted to the HDU and 185 to the
ICU. The median age (IQR) of the patients was 65.9 years
(52.0 to 76). Of these, 93 (42%) were female. Twenty
patients (9.1%) died on the ICU. A total of 115 subjects
(52.5%) were surgical patients. The median length of stay
was three (one to six) days.
A total of 198/219 patients (91.8%) met two or more
of the SIRS criteria in the first 24 hours of admission to
ICU. Interrater reliability for classification of these as
sepsis or having a non-infective aetiology was high
(Cohen’s kappa 0.8) but in 36 patients (18.2%) it was
not possible to determine with certainty whether infec-
tion was present or not. This group included four
patients with pancreatitis. A total of 87/198 patients
with SIRS (43.9%) were deemed to have sepsis, while 75
(37.9%) were deemed not to have infection and were
thus classified as having non-infective SIRS. Demo-
graphic and clinical features of the different patient
groups are shown in Table 1. Among patients with a
systemic inflammatory response, those with organ dys-
function were less likely to be on the HDU, were less
often post-surgical patients and had higher SOFA
scores, but overall, patients with sepsis, non-infective
SIRS and SIRS, which could not be categorised as sepsis
or non-infective, were similar in terms of age, gender
and severity of illness.
Overall, 20 patients (9.1%) died during admission to
HDU/ICU. Among patients with severe sepsis, 12 (16%)
died compared with 4 (8%) of patients with severe non-
infective SIRS. Patients with sepsis on admission to ICU
had a longer median length of stay than patients with
non-infective SIRS; 4.1 vs 2.4 days (P = 0.01).
The microbiological and infection characteristics of the
sepsis patients are summarised in Table 2. The great
majority of sepsis patients had a focus of infection either
in the respiratory tract or abdomen. Infection was micro-
biologically proven in 33/87 patients with sepsis (38%) and
diagnosed on radiological or clinical grounds in the
remainder. Of 75 patients with non-infective SIRS, 29
were post-surgical (maxillofacial, urological), 11 cardiac
(surgery or out-of-hospital cardiac arrest), 9 trauma and
the remainder had a mixture of medical pathologies, (drug
overdose, gastro-intestinal haemorrhage, diabetic ketoaci-
dosis, acute asthma, seizures, pulmonary embolism,
dehydration).
Biomarker levels
C-reactive protein was measured for clinical purposes in
143 of the study subjects and this information was avail-
able to the clinicians categorising subjects for the study.
Consequently, the performance of CRP as a biomarker
could not be assessed. Of note though, while levels of CRP
measured in the study samples were markedly higher in
patients with sepsis than in patients with non-infective
SIRS (146 (105 to 203) vs 9.5 (3.4 to 19.9) (P < 0.001)),
there was no difference in CRP depending on severity of
illness (data not shown).
Plasma levels of the different biomarkers measured in
the study are shown in Figure 1. Levels of PCT (3.1 (0.8 to
3.9) vs 0.2 (0.1 to 0.8) (P < 0.001)), sCD25, (4.5 (3.0 to 6.1)
vs 1.5 (1.1 to 2.1) (P < 0.001)), PSP (116 (50 to 216) vs
16.5 (11.1 to 27.9) (P < 0.001)) and IL6 (373 (150 to 1435)
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vs 83.5 (31 to 261) (P < 0.001)) were higher in patients
with sepsis than in patients with non-infective SIRS. PSP
was the only marker for which levels were significantly
higher in patients with severe sepsis than patients with
non-severe sepsis (157 (56 to 310) vs 59 (39 to 88) (P =
0.01)). Levels of HBP were similar in all patient groups.
Among the 36 patients who could not be classified as hav-
ing sepsis or non-infective SIRS, there were no significant
differences between those with severe and non-severe dis-
ease. The other cytokines tested for were only detected in
a minority of patients as follows: IL1b, 84 (36.4%),
GMCSF, 26 (11.9%) and TNFa 5 (2.3%). A detectable level
of these markers was more common in patients with sep-
sis than patients with non-infective SIRS: IL1b 61% vs
15%, GMCSF 26% vs 1% and TNFa 3% vs 0%. The small
proportion of sepsis patients with detectable levels of
TNFa is likely to be due to the fact that samples were
taken with relation to the time of admission to ICU rather
than the onset of sepsis.
These differences were reflected in the ROC analysis
shown in Figure 2. For each marker, co-ordinates of the
ROC curve were used to select optimal cut-offs for dis-
tinguishing sepsis from non-infective SIRS. These cut-
offs are shown on Figure 1 and the performance of each
marker is set out in Table 3. Although AUCs for PSP
and sCD25 were higher than for PCT in differentiating
sepsis from non-infective SIRS these differences were
not statistically significant
Relationship between biomarkers and severity of illness
We set out to assess the performance of each marker in
terms of reflecting illness severity first by analysing
those 126 patients who had severe sepsis or non-infec-
tive SIRS (severe being defined by a SOFA score of 2 or
more for any organ system). Of these 126 patients, 76
had severe sepsis and 50 severe non-infective SIRS. By
ROC analysis PSP, sCD25 and PCT all performed well
with AUCs over 0.8 (Figure 2). The performance of
each marker is set out in Table 4. The AUCs for PSP
and sCD25 were again higher than for PCT but these
differences were not statistically significant.
To look more closely at the ability of biomarkers to
reflect severity of illness, patients with non-infective
SIRS and sepsis were grouped according to SOFA score
with severity defined as mild (SOFA 0 to 3), moderate
(SOFA 4 to 6) and severe (SOFA > = 7). For both PCT
Table 1 Base-line characteristics and outcome of patients included in the study
Variable SIRS criteria
not fulfilled
SIRS not categorised as
sepsis or non-infective
Non-infective SIRS Sepsis
Without organ
dysfunction
With organ
dysfunction
Without organ
dysfunction
With organ
dysfunction
N 21 36 25 50 11 76
Age (years) (IQR) 72.1 (61.5 to
75.4)
66.8 (40.5 to 77.5) 63.3 (51.2 to 71.5) 62.6 (51.0 to
74.5)
65.1 (42.6 to 73.4) 66.7 (54.3. to
75.8)
Female, n (%) 5 (29%) 19 (53%) 11 (44%) 21 (42%) 6 (54%) 30 (39%)
HDU, n (%) 6 (33%) 4 (11%) 11 (44%) 4 (8%) 4 (36%) 4 (5%)
Surgical 14 (78%) (36%) 20 (80%) 19 (38%) 10 (91%) 36 (47%)
SOFA score Day 1 (IQR) 4 (3 to 7) 5 (3 to 8) 1 (1 to 2) 6 (3 to 8) 2 (1 to 3) 7 (5 to 10)
Length of stay on ICU/
HDU (days) (IQR)
2.8 (1.3 to 8.3) 3.4 (1.3 to 8.6) 1.3 (0.3 to 3.1) 2.4 (1.1 to 5.1) 1.8 (1.3 to 10) 4.1 (2.4 to 7.8)
Mortality on ICU/HDU
n (%)
0 3 (8%) 1 (4%) 4 (8%) 0 12 (16%)
Table 2 Microbiological and infection characteristics of
the sepsis patients
Variable Non-severe
sepsis
N = 11
Severe
sepsis
N = 76
Total
N = 87
Assessment of
infection
Microbiologically
proven
4 (36%) 29 (38%) 33
(38%)
Gram-positive bacterial 2 4 6
Gram-negative bacterial 2 15 17
Polymicrobial 0 1 1
Viral 0 9a 9
Radiological diagnosis 0 (0%) 8 (11%) 8 (9%)
Clinical diagnosis 7 (64%) 39 (51%) 46
(53%)
Bacteraemic 2 (18%) 5 (7%) 7 (8%)
Focus of infection
Respiratory tract 1 (9%) 32 (42%) 33 (38%)
Abdomen 8 (73%) 30 (39%) 38 (44%)
Urinary tract 0 (0%) 5 (7%) 5 (6%)
Skin and soft tissue 2 (18%) 5 (7%) 7 (8%)
Other 0 (0%) 4 (5%) 4 (5%)
aSeven patients had proven influenza A and may have had bacterial
superinfection but this was not proven microbiologically, one had
parainfluenza and another Respiratory Syncytial Virus infection.
Llewelyn et al. Critical Care 2013, 17:R60
http://ccforum.com/content/17/2/R60
Page 4 of 11
and PSP there was a clear relationship between plasma
level and severity of sepsis but not severity of non-infec-
tive SIRS (Figure 3). Focusing on patients with SOFA
score > = 7, the AUC for PSP in discrimination of sepsis
from non-infective SIRS was higher at 0.955 (0.909 to 1)
vs 0.837 (0.732 to 0.941). However, this difference was
not statistically significant.
Regression analysis and evaluation of combined
performance of biomarkers
In univariate regression analysis, for both PSP (cut-off 30
ng/ml) and sCD25 (cut-off 2.5 ng/ml), elevation was
strongly associated with sepsis compared with non-infec-
tive SIRS and severe sepsis compared with non-severe
SIRS of non-infective aetiology (Table 5). For both
Figure 1 Biomarker levels in patients with SIRS at the time of admission to intensive/high dependency care. Boxes show medians and
IQRs, whiskers show the 5th and 95th percentiles. Dotted horizontal lines show cut-offs defined by ROC analysis for distinguishing sepsis from
non-infective SIRS. Brackets show statistically significant differences (independent samples T-test) as follows; * P < 0.001, **P < 0.01, *** P < 0.05).
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markers, the odds ratios for sepsis were higher than for
PCT but not-statistically significantly so as the 95% confi-
dence intervals overlap. Elevation of HBP above the cut-
off of 50 ng/ml was not statistically associated with either
sepsis or severe sepsis.
Calculation of correlation coefficients for the different
variables revealed a marked degree of correlation
between the markers (see Additional file 1). Correlation
coefficients for PSP, sCD25 and IL6 with PCT were
between 0.55 and 0.59. HBP showed poor correlation
with other markers. Markers for which the ROC was >
0.8 were selected to include in the logistic regression
analysis (PSP, sCD25 and IL6 with PCT). In a forward,
stepwise, logistic regression analysis, the addition of
sCD25 improved the performance of both PCT and
PSP, improving the AUC of these markers alone for dif-
ferentiating severe sepsis from severe non-infective SIRS
(Table 4) from 0.84 and 0.91 to 0.89 (0.83 to 0.95) and
0.94 (0.90 to 0.98), respectively. Among patients with
severe sepsis, 56 had levels of both PSP and sCD25
above the cut-off while only 4 had levels below the cut-
off for both markers. In 16 patients, the markers were
discordant. Conversely, in patients with severe non-
infective SIRS only 2 patients had elevation of both mar-
kers while 31 had levels of both below the cut-off. In 17
patients, the markers were discordant. The negative pre-
dictive value of low PSP and low sCD25 was thus 89%
and the positive predictive value of high PSP and high
sCD25 was 97%, with 33/126 (26.2%) having discordant
results. No improvement in the sensitivity or specificity
was observed with other combinations of markers.
Discussion
The main findings of this study, performed in patients at
the time of admission to intensive or high dependency
care, are: 1) that two recently described sepsis biomar-
kers (PSP and sCD25) perform at least comparably with
PCT in identifying patients with sepsis; 2) PSP shares
with PCT the property of reflecting sepsis severity; 3)
HBP, despite promise in other settings, does not appear
Figure 2 Receiver Operating Characteristic curves for biomarkers. A) 162 patients with either sepsis or non-infective SIRS. B) 126 patients
with dysfunction of one or more organ system (SOFA score ≥ 2 and either sepsis or non-infective SIRS. Data for GMCSF and TNFa are not
shown as only a minority of patients had detectable levels of these markers.
Table 3 Diagnostic performance of biomarkers.
Marker AUC (95% CI) Cut off Sensitivity Specificity PPV NPV
PCT 0.84 (0.78 to 0.90) 1.0 ng/ml 71% 82% 83% 71%
PSP 0.93 (0.89 to 0.97) 30 ng/ml 90% 83% 86% 87%
sCD25 0.90 (0.85 to 0.95) 2.5 ng/ml 83% 83% 85% 81%
HBP 0.60 (0.52 to 0.69) 50 ng/ml 78% 36% 59% 59%
IL6 0.81 (0.74 to 0.87) 200 pg/ml 68% 68% 71% 65%
IL8 0.78 (0.71 to 0.85) 80 pg/ml 78% 63% 71% 71%
IL1b 0.76 (0.69 to 0.84) 1.0 pg/ml 61% 88% 86% 69%
Biomarker performance is shown for 162 patients in distinguishing sepsis (n = 87) from SIRS without an infective aetiology (n = 75) Data for GMCSF and TNFa
are not shown as only a minority of patients had detectable levels of these markers.
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to perform well in this population; 4) a combinatorial
approach to biomarker use might offer better discrimi-
nation in sepsis than use of a single biomarker alone.
Our study has several important strengths. Unlike the
majority of sepsis biomarker studies which enrol very
specific patient groups, we have tested these markers in
unselected patients with the diverse range of patholo-
gies, infective and otherwise, which present to high
dependency and intensive care units. By using well
established and objective outcome categories and incor-
porating all available clinical information we have been
able to define groups of patients with either sepsis or
non-infective SIRS. This has allowed us to assess the
biomarkers without including clinically unrealistic con-
trol patients without suspected infection or sepsis.
Previous studies of PSP have reported elevated levels
in patients following non-pancreatic trauma which
reflect severity in trauma patients who develop infection
[10]. In patients with ventilator-associated pneumonia,
levels of PSP at the time of diagnosis correlate with
severity of illness and survival [12]. In keeping with
these observations we find that while most patients at
the time of admission to intensive care have elevated
PSP levels, this does reflect the presence of sepsis and
severity of illness to a degree which is comparable to
PCT. We excluded from this analysis four patients with
acute pancreatitis not because of the possible effect of
this on PSP level but because it was not possible in
these patients to be certain whether infection was pre-
sent. Notably, all four patients had elevated levels of
PSP. We did not exclude from the analysis patients with
renal impairment or gastrointestinal pathologies.
Levels of sCD25 in the blood appear to reflect the
level of CD25 expression on activated T cells which has
been suggested as a marker of activation-induced regu-
latory T cell response [14]. Whereas levels of acute
phase reactants, such as PCT and PSP, reflect the mag-
nitude of an inflammatory response, expression of CD25
may reflect the development of a compensatory anti-
inflammatory state and thus provide additional informa-
tion about an individual’s response to sepsis at a point
in time [13]. Our findings are in keeping with those of
Saito et al. who found higher levels of sCD25 in 20 sep-
sis patients than 16 patients with non-infective SIRS
[14]. More recently, Lvovschi et al. performed multiplex
cytokine analysis on 126 patients presenting to the
emergency department with non-infective SIRS or sepsis
[21]. Although they were unable to demonstrate profiles
characteristic of sepsis, sCD25 was the only marker
independently associated with severe sepsis in multivari-
ate analysis. Interestingly, sCD25 levels were generally
lower among the patients in that study (median value <
1 ng/ml) and lower among patients with severe sepsis
than in patients with mild disease. These differences
probably reflect sampling time relative to the onset of
sepsis and emphasise the importance of not extrapolat-
ing data from sepsis biomarker studies performed in
one setting to another.
The poor performance of HBP in differentiating sepsis
from non-infective SIRS in this study suggests that the
value of this marker should be further explored in the
emergency department rather than in the intensive care
setting. Linder et al. measured HBP in febrile adults
presenting to the emergency department and showed
that levels ≥ 15 ng/ml were a better indicator of severe
sepsis or septic shock than procalcitonin [15]. Subse-
quent studies by the same group have demonstrated ele-
vated levels of HBP in cerebrospinal fluid of patients
with bacterial meningitis and the urine of children with
urinary tract infections [22,23]. Our findings contrast
with three previous studies of HBP conducted in ICU.
Berkestedt et al. reported elevated HBP levels correlat-
ing with severity in 33 patients with severe sepsis [24],
while Chew et al. found elevated levels of HBP in 53
patients with shock on the ICU irrespective of infectious
aetiology and no correlation with severity and outcome
[25]. More recently, Linder et al. reported higher HBP
levels in patients with sepsis than with non-septic criti-
cal illness on ICU and a correlation with mortality.
However, 50% of control patients had elevated HBP
levels. It is possible that the lack of a relationship
between HBP level and infection or severity of illness in
Table 4 Diagnostic performance of biomarkers in distinguishing sepsis from non-infective SIRS in patients with organ
dysfunction.
Marker AUC (95% CI) Cut off Sensitivity Specificity PPV NPV
PCT 0.84 (0.77 to 0.91) 1.0 ng/ml 74% 81% 86% 67%
PSP 0.91 (0.86 to 0.96) 30 ng/ml 88% 78% 86% 81%
sCD25 0.87 (0.81 to 0.93) 2.5 ng/ml 80% 78% 85% 72%
HBP 0.58 (0.48 to 0.68) 50 ng/ml 78% 38% 66% 53%
IL6 0.82 (0.74 to 0.89) 200 pg/ml 71% 66% 76% 60%
IL8 0.76 (0.68 to 0.84) 80 pg/ml 82% 58% 75% 67%
IL1b 0.77 (0.69 to 0.85) 1.0 pg/ml 65% 88% 89% 62%
Biomarker performance is shown for 76 patients with severe sepsis and 50 patients with non-infective SIRS and organ dysfunction. Data for GMCSF and TNFa are
not shown as only a minority of patients had detectable levels of these markers.
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Figure 3 Relationship between biomarker levels and severity of illness. Boxes show medians and IQRs, whiskers show 5th and 95th
percentiles. Brackets show statistically significant differences in pairwise group comparisons (independent samples T-test) as follows; * P < 0.001,
**P < 0.01, *** P < 0.05).
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our study relates to the unselected nature of the patients
we recruited.
Other studies have reported the use of combinations of
sepsis biomarkers to increase diagnostic accuracy driven
in part by the availability of multiplex platforms allowing
panels of markers to be assessed simultaneously. The
high degree of correlation which we and others have
observed between inflammatory markers represents the
main challenge to a combinatorial approach [21]. The
increase in accuracy we observe from adding sCD25 to
PSP or PCT raises the possibility of increased value that
can be gained from choosing markers of different arms of
the inflammatory response (neutrophils, acute phase pro-
teins, cytokines, T cell activation/regulatory markers).
Our study has some important limitations. To perform
ROC analysis and calculate predictive values for each
marker, we have had to classify patients as having sepsis
or non-infective SIRS, but as a result of the study being
observational and having unselected entry criteria, 18% of
patients with SIRS could not be robustly characterised as
having either sepsis or a non-infective aetiology. While
this is the patient group in which a novel marker might
be most valuable, our study was not designed to address
this. The studies needed to establish whether PSP or
sCD25 could improve diagnosis in this most challenging
patient group would require protocolised investigation of
patients and multicentre recruitment. They would thus
be expensive and time consuming. Our findings indicate
that PSP and sCD25 may be good candidates to take for-
ward into such studies.
An additional limitation is that we have assessed the
markers’ performance in identifying sepsis and severe sep-
sis only at the time of sampling. Thus, we cannot draw
conclusions about the predictive value of the markers for
the development of sepsis at a later time or assess the
impact of serial measurements. Furthermore, the average
SOFA score of patients in our study is relatively low con-
sidering this is an ICU-based sepsis study as is the propor-
tion of sepsis patients where a firm microbiological
diagnosis was made. Both of these criticisms are inherent
in the study’s design which prioritised recruitment of
unselected subjects at the time of admission over long-
term follow-up of highly selected patients. The advantage
of this approach is that it has allowed us to perform a chal-
lenging, real-life assessment of these markers which should
now inform the design of the larger studies, with more
detailed follow-up, which are required to determine which
markers could predict the development of sepsis or the
progression of severity in sepsis for patients in ICU or
HDU.
Conclusions
Candidate sepsis biomarkers are often first described in
studies focussing on selected patient groups and fail to
translate into routine clinical practice. We have per-
formed an assessment of three promising markers among
unselected patients with a systemic inflammatory
response and in a clinical setting where sepsis biomarkers
are commonly used, at the time of a patient’s admission
to intensive or high dependency care. Two markers (PSP
and sCD25) performed well in this setting, while the
third (HBP) did not. Our findings support the further
assessment of PSP and sCD25 to inform clinical decision
making in patients with suspected sepsis in the high-
dependency care setting.
Key messages
• Candidate sepsis biomarkers that show promise in
highly selected patient groups should be validated in
studies which recruit unselected patients more typi-
cal of clinical practice. This approach represents an
important stepping-stone between the first descrip-
tion of a marker and its validation in the time-con-
suming and expensive intervention studies, which
are required for introduction to clinical practice.
• Two of the markers studied here, PSP and sCD25,
perform well in differentiating sepsis from non-infec-
tive illnesses and warrant further study in critical
care patients. The third, HBP, does not appear to
perform well in this setting.
Table 5 Biomarker levels according study group.
Cut off SIRS
N = 75
Sepsis
N = 87
OR P Severe SIRS
N = 50
Severe sepsis
N = 76
OR P
PCT 1.0 ng/ml 13/74* 62/87 11.6 (5.5 to 24.8) < 0.0001 9/49* 56/76 12.4 (5.1 to 30.2) < 0.0001
PSP 30 ng/ml 13/75 78/87 41.3 (16.6 to 103.0) < 0.0001 11/50 67/76 26.4 (10.1 to 69.3) < 0.0001
sCD25 2.5 ng/ml 13/75 72/87 22.9 (10.1 to 51.8) < 0.0001 11/50 61/76 14.4 (6.0 to 34.7) < 0.0001
HBP 50 ng/ml 48/75 68/87 2.0 (1.0 to 4.0) 0.06 31/50 59/76 2.1 (1.0 to 4.7) 0.07
IL6 200 ng/ml 24/75 59/87 4.5 (2.3 to 8.7) < 0.0001 17/50 54/76 4.8 (2.2 to 10.3) < 0.0001
IL8 80 ng/ml 28/75 68/87 6.0 (3.0 to 12.0) < 0.0001 21/50 62/76 6.1 (2.7 to 13.7) < 0.0001
IL1b 1.0 ng/ml 9/75 57/87 13.9 (6.1 to 31.8) < 0.0001 6/50 49/76 13.3 (5.5 to 35.3) < 0.0001
Univariate odds ratios (95% confidence intervals) are given for sepsis or severe sepsis using cut-offs derived by ROC analysis. * One patient with severe SIRS did
not have PCT measured.
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• The performance of sepsis biomarkers may vary
between clinical settings, such as the emergency
room and the intensive care unit.
Additional material
Additional file 1: Correlation between biomarkers. A table showing
correlations for all the biomarkers and inflammatory mediators measured.
For each, correlation coefficients are shown. Correlation coefficients
greater than 0.5 are highlighted in red.
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